TRTL-913 in Healthy Volunteers and Adults With Tinnitus

Phase 2, randomised, double-blind trial of TRTL-913 in tinnitus (3 arms), sponsored by Tortugas Neuroscience. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Number of Participants with Clinically Significant Change From Baseline in Vital Signs, Clinical Laboratory Values, and Electrocardiograms (ECGs) and 1 more. Started Oct 2026; status: recruiting.